<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02420717</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0521</org_study_id>
    <secondary_id>NCI-2015-00779</secondary_id>
    <secondary_id>2014-0521</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02420717</nct_id>
  </id_info>
  <brief_title>Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia</brief_title>
  <official_title>A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effects and best dose of ruxolitinib phosphate and how
      well it works compared to dasatinib when given with chemotherapy in treating patients with
      Philadelphia chromosome-like acute lymphoblastic leukemia that has come back (relapsed) or
      has not responded to treatment (refractory). Ruxolitinib phosphate and dasatinib may stop the
      growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
      chemotherapy work in different ways to stop the growth of cancer cells, either by killing the
      cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
      known whether giving ruxolitinib phosphate or dasatinib with chemotherapy works better in
      treating patients with previously treated acute lymphoblastic leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the safety and maximal tolerated dose (MTD) of ruxolitinib phosphate
      (ruxolitinib) in combination with chemotherapy in patients with Philadelphia chromosome
      (Ph)-like acute lymphoblastic leukemia (ALL). (Phase I, ruxolitinib cohort only) II. To
      determine the response rate (complete response [CR]/CR with incomplete marrow recovery [CRi])
      of ruxolitinib or dasatinib in combination with chemotherapy in patients with Ph-like ALL.
      (Phase II)

      SECONDARY OBJECTIVES:

      I. To determine the response rate (CR/CRi) of ruxolitinib in combination with chemotherapy in
      patients with Ph-like ALL. (Phase I, ruxolitinib cohort only) II. To determine the duration
      of response, disease-free survival and overall survival of ruxolitinib in combination with
      chemotherapy in patients with Ph-like ALL. (Phase I, ruxolitinib cohort only) III. To
      determine the safety and toxicity profile of ruxolitinib or dasatinib in combination with
      chemotherapy in patients with Ph-like ALL. (Phase II) IV. To determine the duration of
      response, disease-free survival and overall survival of ruxolitinib or dasatinib in
      combination with chemotherapy in patients with Ph-like ALL. (Phase II)

      OUTLINE: This is a phase I, dose escalation study of ruxolitinib followed by a phase II
      study. Patients are assigned to 1 of 2 cohorts.

      COHORT A: Patients receive ruxolitinib phosphate orally (PO) twice daily (BID). Cycles repeat
      every 21 days in the absence of disease progression or unacceptable toxicity.

      COHORT B: Patients receive dasatinib PO once daily (QD). Cycles repeat every 21 days in the
      absence of disease progression or unacceptable toxicity.

      INTENSIVE CHEMOTHERAPY: After cycle 1, patients not achieving a response also receive
      cyclophosphamide intravenously (IV) over 3 hours BID on days 1-3, doxorubicin IV over 24-48
      hours on day 4, vincristine IV over 30 minutes on days 4 and 11, and dexamethasone PO QD or
      IV over 30 minutes on days 1-4 and 11-14 of cycles 1, 3, 5, and 7. Patients receive
      methotrexate IV over 24 hours on day 1, leucovorin IV over 1 hour or PO every 6 hours on days
      2-5, cytarabine IV over 2 hours BID on days on days 2 and 3 of cycles 2, 4, 6, and 8. At the
      discretion of the treating physician, patients may also receive rituximab IV over several
      hours on days 1 and 11 of cycles 1 and 3 and on days 1 and 8 of cycles 2 and 4 only.
      Treatment repeats every 21 days for up to 8 cycles in the absence of disease progression or
      unacceptable toxicity.

      MAINTENANCE THERAPY: Patients receive mercaptopurine PO thrice daily (TID), methotrexate PO
      once a week, vincristine IV over 30 minutes on day 1, and prednisone PO on days 1-5. Cycles
      repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed up at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2015</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal tolerated dose (MTD) of ruxolitinib in combination with chemotherapy defined as the highest dose level at which no more than 1 out of 6 patients experience a dose limiting toxicity (Phase I)</measure>
    <time_frame>42 days</time_frame>
    <description>The method of Thall, Simon and Estey will be used for toxicity monitoring for this study. The severity of the toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 whenever possible. Safety data will be summarized by category, severity and frequency.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete response (complete response [CR]/CR with incomplete marrow recovery [CRi]) (Phase II)</measure>
    <time_frame>42 days</time_frame>
    <description>The optimum two-stage design proposed by Simon will be implemented in each of the cohorts separately. The response rate (CR/CRi) will be estimated along with the confidence interval in each cohort.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>The method of Thall, Simon and Estey will be used for toxicity monitoring for this study. The severity of the toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 whenever possible. Safety data will be summarized by category, severity and frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Duration of response will be estimated using the Kaplan-Meier method. The association of the time to event outcomes with patient characteristics will be evaluated using the log rank test and Cox proportional hazards regression analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 30 days after completion of study treatment</time_frame>
    <description>Progression-free survival will be estimated using the Kaplan-Meier method. The association of the time to event outcomes with patient characteristics will be evaluated using the log rank test and Cox proportional hazards regression analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Recurrent B Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Ph-Like Acute Lymphoblastic Leukemia</condition>
  <condition>Refractory B Acute Lymphoblastic Leukemia</condition>
  <condition>Refractory Ph-Like Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ruxolitinib phosphate PO BID. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive dasatinib PO QD. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-Cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
    <other_name>BMS-354825</other_name>
    <other_name>Dasatinib Hydrate</other_name>
    <other_name>Dasatinib Monohydrate</other_name>
    <other_name>Sprycel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
    <other_name>Aacidexam</other_name>
    <other_name>Adexone</other_name>
    <other_name>Aknichthol Dexa</other_name>
    <other_name>Alba-Dex</other_name>
    <other_name>Alin</other_name>
    <other_name>Alin Depot</other_name>
    <other_name>Alin Oftalmico</other_name>
    <other_name>Amplidermis</other_name>
    <other_name>Anemul mono</other_name>
    <other_name>Auricularum</other_name>
    <other_name>Auxiloson</other_name>
    <other_name>Baycadron</other_name>
    <other_name>Baycuten</other_name>
    <other_name>Baycuten N</other_name>
    <other_name>Cortidexason</other_name>
    <other_name>Cortisumman</other_name>
    <other_name>Decacort</other_name>
    <other_name>Decadrol</other_name>
    <other_name>Decadron</other_name>
    <other_name>Decadron DP</other_name>
    <other_name>Decalix</other_name>
    <other_name>Decameth</other_name>
    <other_name>Decasone R.p.</other_name>
    <other_name>Dectancyl</other_name>
    <other_name>Dekacort</other_name>
    <other_name>Deltafluorene</other_name>
    <other_name>Deronil</other_name>
    <other_name>Desamethasone</other_name>
    <other_name>Desameton</other_name>
    <other_name>Dexa-Mamallet</other_name>
    <other_name>Dexa-Rhinosan</other_name>
    <other_name>Dexa-Scheroson</other_name>
    <other_name>Dexa-sine</other_name>
    <other_name>Dexacortal</other_name>
    <other_name>Dexacortin</other_name>
    <other_name>Dexafarma</other_name>
    <other_name>Dexafluorene</other_name>
    <other_name>Dexalocal</other_name>
    <other_name>Dexamecortin</other_name>
    <other_name>Dexameth</other_name>
    <other_name>Dexamethasone Intensol</other_name>
    <other_name>Dexamethasonum</other_name>
    <other_name>Dexamonozon</other_name>
    <other_name>Dexapos</other_name>
    <other_name>Dexinoral</other_name>
    <other_name>Dexone</other_name>
    <other_name>Dinormon</other_name>
    <other_name>Fluorodelta</other_name>
    <other_name>Fortecortin</other_name>
    <other_name>Gammacorten</other_name>
    <other_name>Hexadecadrol</other_name>
    <other_name>Hexadrol</other_name>
    <other_name>Lokalison-F</other_name>
    <other_name>Loverine</other_name>
    <other_name>Methylfluorprednisolone</other_name>
    <other_name>Millicorten</other_name>
    <other_name>Mymethasone</other_name>
    <other_name>Orgadrone</other_name>
    <other_name>Spersadex</other_name>
    <other_name>TaperDex</other_name>
    <other_name>Visumetazone</other_name>
    <other_name>ZoDex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
    <other_name>Adriablastin</other_name>
    <other_name>Hydroxydaunomycin</other_name>
    <other_name>Hydroxyl Daunorubicin</other_name>
    <other_name>Hydroxyldaunorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
    <other_name>Folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
    <other_name>3H-Purine-6-thiol</other_name>
    <other_name>6 MP</other_name>
    <other_name>6 Thiohypoxanthine</other_name>
    <other_name>6 Thiopurine</other_name>
    <other_name>6-Mercaptopurine</other_name>
    <other_name>6-Mercaptopurine Monohydrate</other_name>
    <other_name>6-MP</other_name>
    <other_name>6-Purinethiol</other_name>
    <other_name>6-Thiopurine</other_name>
    <other_name>6-Thioxopurine</other_name>
    <other_name>6H-Purine-6-thione, 1,7-dihydro- (9CI)</other_name>
    <other_name>7-Mercapto-1,3,4,6-tetrazaindene</other_name>
    <other_name>Alti-Mercaptopurine</other_name>
    <other_name>Azathiopurine</other_name>
    <other_name>Bw 57-323H</other_name>
    <other_name>Flocofil</other_name>
    <other_name>Ismipur</other_name>
    <other_name>Leukerin</other_name>
    <other_name>Leupurin</other_name>
    <other_name>Mercaleukim</other_name>
    <other_name>Mercaleukin</other_name>
    <other_name>Mercaptina</other_name>
    <other_name>Mercaptopurinum</other_name>
    <other_name>Mercapurin</other_name>
    <other_name>Mern</other_name>
    <other_name>NCI-C04886</other_name>
    <other_name>Puri-Nethol</other_name>
    <other_name>Purimethol</other_name>
    <other_name>Purine, 6-mercapto-</other_name>
    <other_name>Purine-6-thiol (8CI)</other_name>
    <other_name>Purine-6-thiol, monohydrate</other_name>
    <other_name>Purinethiol</other_name>
    <other_name>Purinethol</other_name>
    <other_name>U-4748</other_name>
    <other_name>WR-2785</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
    <other_name>Abitrexate</other_name>
    <other_name>Alpha-Methopterin</other_name>
    <other_name>Amethopterin</other_name>
    <other_name>Brimexate</other_name>
    <other_name>CL 14377</other_name>
    <other_name>CL-14377</other_name>
    <other_name>Emtexate</other_name>
    <other_name>Emthexat</other_name>
    <other_name>Emthexate</other_name>
    <other_name>Farmitrexat</other_name>
    <other_name>Fauldexato</other_name>
    <other_name>Folex</other_name>
    <other_name>Folex PFS</other_name>
    <other_name>Lantarel</other_name>
    <other_name>Ledertrexate</other_name>
    <other_name>Lumexon</other_name>
    <other_name>Maxtrex</other_name>
    <other_name>Medsatrexate</other_name>
    <other_name>Metex</other_name>
    <other_name>Methoblastin</other_name>
    <other_name>Methotrexate LPF</other_name>
    <other_name>Methotrexate Methylaminopterin</other_name>
    <other_name>Methotrexatum</other_name>
    <other_name>Metotrexato</other_name>
    <other_name>Metrotex</other_name>
    <other_name>Mexate</other_name>
    <other_name>Mexate-AQ</other_name>
    <other_name>MTX</other_name>
    <other_name>Novatrex</other_name>
    <other_name>Rheumatrex</other_name>
    <other_name>Texate</other_name>
    <other_name>Tremetex</other_name>
    <other_name>Trexeron</other_name>
    <other_name>Trixilem</other_name>
    <other_name>WR-19039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab ABBS</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar JHL1101</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>rituximab biosimilar TQB2303</other_name>
    <other_name>rituximab-abbs</other_name>
    <other_name>RTXM83</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib Phosphate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <other_name>INCB-18424 Phosphate</other_name>
    <other_name>Jakafi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Cohort A (ruxolitinib phosphate)</arm_group_label>
    <arm_group_label>Cohort B (dasatinib)</arm_group_label>
    <other_name>Leurocristine</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincrystine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with previously treated B-cell ALL (relapsed and/or refractory after prior
             therapy)

          -  Bone marrow involvement with &gt;= 5% lymphoblasts

          -  Documented genetic lesion(s) known to confer susceptibility to inhibition by either
             ruxolitinib or dasatinib or cytokine receptor-like factor 2 (CRLF2) positivity by flow
             cytometry (for the ruxolitinib cohort)

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  Total bilirubin &lt; 2.0 mg/dL

          -  Serum glutamate pyruvate transaminase (SGPT) or serum glutamic oxaloacetic
             transaminase (SGOT) &lt; 3 x upper limit of normal (ULN)

          -  Creatinine &lt; 2 mg/dL

          -  Females of childbearing potential must have a negative serum or urine beta human
             chorionic gonadotropin (beta-hCG) pregnancy test result within 14 days prior to the
             first dose of study drugs and must agree to use an effective contraception method
             during the study and for 30 days following the last dose of study drug; females of
             non-childbearing potential are those who are postmenopausal greater than 1 year or who
             have had a bilateral tubal ligation or hysterectomy; appropriate methods of birth
             control include the following: any 2 of the following methods used together: birth
             control implants, injections, or pills (except for progesterone only pills),
             intrauterine device (IUD), vasectomy, tubal ligation, barrier method (female or male
             condom with spermicide, cervical cap with spermicide, diaphragm with spermicide); male
             condom with spermicide and diaphragm; male condom with spermicide and cervical cap;
             unacceptable methods of birth control include using no birth control, withdrawal,
             rhythm method, vaginal sponge, any barrier method that does not use spermicide,
             progesterone only pills, and using male and female condoms at the same time

          -  Males who have partners of childbearing potential must agree to use an effective
             contraceptive method during the study and for 30 days following the last dose of study
             drug

          -  Patients or their legally authorized representative must provide written informed
             consent

        Exclusion Criteria:

          -  Burkitt's leukemia or lymphoma, T-cell ALL or lymphoblastic lymphoma

          -  Patients having undergone prior allogeneic stem cell transplant within 3 months or
             having active graft versus host disease

          -  Patient is pregnant or breastfeeding

          -  Patients with uncontrolled active infections (fever &gt;= 38 degrees Celsius [C], septic
             shock)

          -  Isolated extramedullary relapse (i.e. testicular, central nervous system)

          -  Current or chronic hepatitis B or C infection, or known seropositivity for human
             immunodeficiency virus (HIV)

          -  Concurrent chemotherapy (except intrathecal chemotherapy)

          -  Major surgery within 4 weeks prior to first study dose

          -  Systemic chemotherapy/radiotherapy/investigational therapy within 14 days (with the
             exception of hydroxyurea and steroids) prior to starting therapy; for patients
             receiving ALL maintenance with 6-mercaptopurine, methotrexate, vincristine, and
             steroids - these agents should be discontinued at least 48 hours prior to start of
             study drugs; for patients on oral targeted therapies (such as imatinib, dasatinib,
             ponatinib), - these agents should be discontinued at least 48 hours prior to start of
             study drugs

          -  Patients must have recovered from acute non hematologic toxicity (to =&lt; grade 1) of
             all previous therapy prior to enrollment

          -  Known active central nervous system (CNS) leukemia, as defined by unequivocal
             morphologic evidence of lymphoblasts in the cerebrospinal fluid (CSF), use of
             CNS-directed local treatment for active disease within the prior 28 days, symptomatic
             CNS leukemia (i.e., cranial nerve palsies or other significant neurologic dysfunction)
             within 28 days; patients may have history of CNS leukemic involvement if definitively
             treated with prior therapy and no evidence of active disease (defined as &gt;= 2
             consecutive spinal fluid assessments with no evidence of disease) at the time of
             registration; prophylactic intrathecal chemotherapy is not a criterion for exclusion

          -  Patients with active heart disease (New York Heart Association [NYHA] class 3-4 as
             assessed by history and physical examination, unstable angina/stroke/myocardial
             infarction within the last 6 months)

          -  Patients with a cardiac ejection fraction (as measured by either multi-gated
             acquisition [MUGA] scan or echocardiogram) &lt; 40%; (Note: patients who have had prior
             anthracycline exposure of &gt; 250 mg/m^2 may be eligible after discussion with the
             principal investigator [PI])

          -  Second malignancy other than basal cell or squamous cell carcinoma of the skin or in
             situ carcinoma of the cervix or the breast, unless they are successfully treated with
             curative intent for more than 2 years before entering the study

          -  Malabsorption syndrome or other conditions that preclude enteral route of
             administration

          -  Patients requiring strong cytochrome P450, family 3, subfamily A, polypeptide 4
             (CYP3A4) inhibitors

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that in the opinion of the investigator may increase the risk associated
             with study participation or investigational product administration or may interfere
             with the interpretation of study results and/or would make the patient inappropriate
             for enrollment into this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nitin Jain</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Dasatinib</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Ichthammol</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

